Cargando…
Novel Trajectories of Bromocriptine Antidiabetic Action: Leptin-IL-6/ JAK2/p-STAT3/SOCS3, p-IR/p-AKT/GLUT4, PPAR-γ/Adiponectin, Nrf2/PARP-1, and GLP-1
Bromocriptine (BC), a sympatholytic dopaminergic D2 receptor agonist, has been comprehensively used in clinic to treat Parkinson’s disease (PD) and prolactinomas. Besides, BC represents a novel therapeutic option in type 2 diabetes (T2DM); however, the precise mechanisms are not completely unveiled....
Autores principales: | Reda, Enji, Hassaneen, Sherifa, El-Abhar, Hanan S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058031/ https://www.ncbi.nlm.nih.gov/pubmed/30072896 http://dx.doi.org/10.3389/fphar.2018.00771 |
Ejemplares similares
-
Bromocriptine Reverses P‐Glycoprotein‐mediated Multidrug Resistance in Tumor Cells
por: Shiraki, Nobuaki, et al.
Publicado: (2002) -
t(8;9)(p22;p24)/PCM1-JAK2 Activates SOCS2 and SOCS3 via STAT5
por: Ehrentraut, Stefan, et al.
Publicado: (2013) -
Antidiabetic effect of an engineered bacterium Lactobacillus plantarum-pMG36e -GLP-1 in monkey model
por: Luo, Jie, et al.
Publicado: (2021) -
MicroRNA-30e-5p Regulates SOCS1 and SOCS3 During Bacterial Infection
por: Mishra, Richa, et al.
Publicado: (2021) -
Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats
por: Fouad Shalaby, Mohammed, et al.
Publicado: (2021)